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We report two cases of successful renal transplantation with allografts from donors who suffered anoxic brain injury as the primary
cause of death fromhouse fires. Eachwas treated prophylacticallywith hydroxocobalamin (Cyanokit) for suspected cyanide toxicity.
During organ procurement, gross examination was notable for deep discoloration of the parenchymal tissues. Approximately 6 and
18 months after transplantation, both recipients have excellent renal graft function and remain independent from hemodialysis
(HD). Hydroxocobalamin is the antidote for suspected acute cyanide toxicity. While largely tolerated by the recipient, there is
concern over the potential functional implications of the associated side effects of dramatic tissue discoloration and development of
oxalate crystals. Furthermore, difficulties performing hemodialysis in patients treated with hydroxocobalamin have been reported
due to discoloration of the effluent fluid impacting the colorimetric sensor, causing false alarms and repetitive interruptions.
As such, many transplant centers in the United States (US) continue to reject these organs. We seek to highlight two cases of
successful transplantation following donor administration of hydroxocobalamin (Cyanokit) and present the first documented
case of successful perioperative intermittent hemodialysis following transplantation of an allograft exposed to hydroxocobalamin.
Furthermore, we emphasize the importance of optimal organ utilization and caution against unnecessary refusal.
1. Introduction
End stage renal disease (ESRD) is a devastating medical
condition representing the most advanced form of chronic
kidney disease (CKD). Five-year survival rates for patients
undergoing renal transplantation are 85.5%, while those on
hemodialysis (HD) are significantly reduced at 35.8% [1–3].
Of the 10,286 deceased donor kidney transplant operations
performed in 2017, asphyxiation was the documented mech-
anism of death for 6% of donors [2]. While the etiology of
asphyxia is multifactorial and diverse, house fires are a major
contributor [2, 4].
Annually, there are approximately 16,000 domestic fire
related injuries and 3,000 deaths [4]. Greater than 75% of
these fatalities are directly attributed to smoke inhalation
toxicity from carbon monoxide (CO) and hydrogen cyanide
(CN) gases [4–6]. CN can be liberated during the combustion
of products containing both carbon and nitrogen, notably
wool, silk, polyurethane (insulation/upholstery), polyacry-
lonitriles (plastics), melamine resins (household goods), and
synthetic rubber [5, 6].
Cyanide is an extremely toxic poison. Mechanistically,
cyanide binds rapidly with cytochrome a3, a component
of the cytochrome c oxidase complex in mitochondria.
Inhibition of cytochrome a3 prevents the cell from using
oxygen and forces anaerobic metabolism, resulting in lactate
production, cellular hypoxia and metabolic acidosis [7, 8].
Untreated, this cascade can lead to death withinminutes.The
presence and extent of cyanide poisoning are often initially
unknown given the absence of a rapid, confirmatory cyanide
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blood test. Thus, treatment decisions must be made on the
basis of clinical history, mechanism of injury, and suspicion
of cyanide intoxication.
The antidote, hydroxocobalamin, classically induces an
abnormal reddish discoloration of renal allografts, and
oxalate crystals on histologic examination are common.
Despite these disconcerting physical features, no evidence
suggests an effect on short- or long-term renal function. The
only issue lies in the potential need for perioperative HD
following renal transplantation. Discoloration of the dialysate
can lead to altered refractive properties as detected by the
HD machine photodetector. Ultimately, this results in the
repetitive triggering of the blood leak alarm initiating a
cascade which halts the blood pump and pauses the dialysis
cycle.
Here we present two cases of successful renal transplan-
tation utilizing organs that were severely discolored due to
prior administration of hydroxocobalamin to the donor and
therefore declined by the majority of other centers in our
region. For both cases, our standard institutional protocols
were followed which specify all patients receive depleting
antibodies as part of their induction regimen. Patients that are
considered immunologically high risk such as those receiving
a second transplant, the presence of donor specific anti-
bodies (DSA), or high calculated panel reactive antibodies
(cPRA) receive anti-thymocyte globulin. Low immunologic
risk patients receive alemtuzumab.
2. Case 1
A 58-year-old female was found unresponsive after a house
fire, with the primary cause of death anoxic brain injury.
Despite a short period of asystole, her renal function was
preserved with an admission creatinine of 0.88, peak creati-
nine of 1.24, and a final creatinine of 1.04. The Kidney Donor
Profile Index (KDPI) was 64%. On gross examination, severe
organ discoloration was noted (Figure 1), and biopsy results
were significant for the presence of oxalate crystals. Kidney
pump pressure was set at 35 mmHg, resulting in a flow of
133 mL/min with a resistance of 0.23 (Table 1). The organ
recipient was a 53-year-old male with end stage renal disease
secondary to hypertensive nephrosclerosis on hemodialysis
three times per week for a total duration of 52 months. His
cPRA was 0% with no evidence of gray zone DSA (Table 2).
A complement dependent cytotoxicity (CDC) T cell cross
match was performed and negative.
Following transplantation, induction immunosuppres-
sion consisted of alemtuzumab 30 mg and solumedrol 500
mg, followed by a maintenance regimen of tacrolimus,
mycophenolate 500mg twice daily and prednisone 10 mg
daily. Early in the perioperative period, the patient’s hospital
course was complicated by severe hyperkalemia and delayed
graft function requiring HD on postoperative day (POD) 1,
2, 4, and 6. Each session was performed without incident.
On POD 7, in the setting of ongoing oliguria and worsen-
ing abdominal distention, laboratory and imaging studies
revealed a large pelvic fluid collection consistentwith an acute
perinephric hematoma. The patient was taken emergently to
the operating room for reexploration and evacuation of the
hematoma. Subsequently, the patient’s urine output began to
improve and serum creatinine started to decrease. Ultimately,
the patient was discharged to home on POD 13.
Approximately 3 weeks after transplant, the patient pre-
sented with an elevated creatinine to 4.70 mg/dL (previous
nadir 2.60 mg/dL). A biopsy of the renal allograft revealed
acute T cell mediated rejection (Banff category 2A) as well as
acute antibody-mediated rejection. A C4D stain was positive
in more than 30% of the peritubular capillaries. A Human
Leukocyte Antigen (HLA) antibody screen revealed a class
II (DQ) DSA at 8000 mean fluorescence intensity (MFI).
Institutional protocols for rejection were followed, and the
patient was initially treated with solumedrol 500mg x3 doses.
Despite this, his creatinine continued to rise and he remained
oliguric. Subsequently, anti-thymocyte globulin 1 mg/kg x
3 doses was administered, followed by plasmapheresis and
IVIG x 5 doses (2g/kg ideal body weight). During this 2-week
hospital readmission for rejection, 4 additional sessions of
HDwere required, and again, there were no complications. A
repeat biopsy 6weeks later did not reveal any signs of ongoing
rejection, and all prior oxalate crystals had disappeared. The
patient’s creatinine improved and plateaued in the 1.9-2.0
range. Eighteen months after transplant, the patient has a
stable graft function with creatinine levels near 2 mg/dL
(Figure 2).
3. Case 2
A 57-year-old male found unresponsive after a house fire
subsequently developed pulseless electrical activity (PEA)
arrest with the primary cause of death documented as anoxic
brain injury. The donor met criteria to be considered public
health services (PHS) high risk given his recent history of
incarceration. Overall, renal function was preserved with
a creatinine on admission of 1.60, peak creatinine of 1.60,
and final creatinine of 1.40. The KDPI was 75%. On gross
examination, severe organ discolorationwas noted (Figure 1),
however, renal biopsy did not reveal the presence of oxalate
crystals. Kidney pumppressurewas set at 35mmHg, resulting
in a flow of 94 mL/min with a resistance of 0.30 (Table 1).
The organ recipient was a 78-year-old male with ESRD
secondary to hypertension and diabetes undergoing HD
three times a week for a total duration of 25 months. The
cPRA was 0%, however, a single gray zone DSA against
HLA A29 was identified (Table 2). All crossmatch tests were
negative.
Induction immunosuppression consisted of anti-
thymocyte globulin (total dose of 5mg/kg) administered over
5 doses and solumedrol 500 mg, followed by a maintenance
regimen of tacrolimus, mycophenolate 500 mg twice daily
and prednisone 10 mg daily. The patient had an overall
uneventful postoperative course with immediate graft
function and progressive downtrend in creatinine levels.
On POD 7, the patient was discharged to a short-term
rehabilitation facility. Six months after organ transplantation,
the patient continues to experience a stable graft function
with baseline creatinine of 1.14 (Figure 2).
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Table 1: Donor demographics and organ parameters.
Donor 1 Donor 2
Age (yrs) 58 57
Sex Female Male
Weight (kg) 94.4 60.8
KDPI∗ (%) 64 75
Cause of Death Anoxia Anoxia
Mechanism House Fire House Fire
Creatinine (mg/dL)
First 0.88 1.60
Peak 1.24 1.60
Last 1.04 1.40
Biopsy at Procurement
Glomerulosclerosis (%) 0 1
Tubular Fibrosis (%) 1-10 1-10
Vessel Atherosclerosis Absent Mild
Oxalate Crystals Positive Negative
Serology
CMV Negative Positive
EBV Negative Positive
HBV Negative Positive
HCV Negative Negative
HIV Negative Negative
NAT∗∗, HBV, HCV, HIV Negative Negative
PHS∗∗∗ Increased Risk Negative Positive
Final Pump Parameters
Pressure (mmHg) 35 35
Flow (mL/min) 133 94
Resistance 0.23 0.30
Organ Laterality Right Right
∗KDPI: Kidney Donor Profile Index.
∗∗NAT: Nucleic Acid Testing.
∗∗∗PHS: U.S. Public Health Service.
Table 2: Recipient demographics.
Recipient 1 Recipient 2
Age (yrs) 53 78
Sex Male Male
Disease Etiology Hypertension Type II Diabetes
Dialysis Duration (months) 52 25
Sequence Match 9 470
cPRA∗ (%) 0 House Fire
Gray zone Antibody Negative A29
CMV Negative Negative
EBV Positive Positive
HBV/HCV Negative Negative
Cold Ischemia Time (hrs) 22 21.65
Warm Ischemia Time (mins) 48 25
∗cPRA: Calculated Panel Reactive Antibody.
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(a) (b)
(c) (d)
(e) (f)
Figure 1: (a) Allograft #1 at time of procurement. (b) Discoloration of effluent. (c) Allograft #1 on pump. (d) Allograft #2 on pump. (e)
Allograft #1 in vivo. (f) Allograft #2 in vivo.
4. Discussion
Cyanide is a lethal toxin which uncouples mitochondrial
oxidative phosphorylation; preventing aerobic metabolism
and initiating a cascade of acidosis and hypoxia. Hydroxo-
cobalamin, the gold standard treatment for cyanide toxicity,
was FDA-approved in the United States in 2006 but has
been formally licensed in Europe since 1996 to treat known
or suspected cyanide poisoning [9]. The initial dose of
hydroxocobalamin for adults is 5 grams administered as an
intravenous (IV) infusion over fifteen minutes. Intravenous
administration of hydroxocobalamin leads to interaction
and binding to plasma proteins and low molecular weight
physiologic compounds generating various cobalamin-(III)
complexes. These molecules can then bind cyanide ions
through a substitution for the hydroxo ligand linked to the
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Figure 2: Serum creatinine (mg/dL) following renal transplan-
tation. Above demonstrates the significant improvement in renal
function after renal transplantation and the sustained viability of
each organ.
trivalent cobalt ion. End product is cyanocobalamin, which
is then excreted in the urine.
Pharmacodynamic effects include an increase in blood
pressure and variable effects on heart rate. Dose-proportional
pharmacokinetics has been observed following adminis-
tration of hydroxocobalamin with total urinary excretion
calculated to be 60-70%of a given dose of hydroxocobalamin.
Discoloration of urine has been noted to occur for up to 35
days after administration. Mean half-life of free cobalamins-
(III) was 26 hours at the 5g dosage. Most common adverse
reactions include chromaturia, erythema, and oxalate crys-
tal formation. These crystals have been observed in the
urine of both healthy subjects given hydroxocobalamin and
patients treated with hydroxocobalamin following suspected
cyanide poisoning [10]. Interestingly, oxalate crystals were
observed in donor 1’s kidney biopsy performed at the time
of organ recovery. Most patients will experience a reversible
red/orange discoloration of the skin, urine and mucous
membrane secretions which can contribute to alterations in
colorimetric tests and co-oximetry measurements [11, 12].
The first published case report of a successful organ trans-
plant from a donor, whose cause of deathwas cyanide toxicity,
was published in 1987 [13]. Several additional case reports
and small series echoed the findings that cyanide toxicity
itself was not a contraindication to transplant [14–17]. Since
2006, hydroxocobalamin has established itself as the gold
standard antidote for cyanide toxicity replacing amyl nitrate
and sodium thiosulfate. Initial reports suggested Cyanokit
administration was safe prior to organ transplantation [18].
However, more recent reports have found hydroxocobalamin
to be associated with failure of intermittent hemodialysis,
thus limiting the opportunity to provide life-saving treatment
should a transplanted allograft fail or experience delayed
function [19, 20]. The presumed mechanism for this phe-
nomenon is the discoloration of bodily fluids triggering a
“pseudo-blood leak” [21]. This triggering of the colorimetric
sensor of the dialysis machine subsequently causes false
alarms and repetitive interruptions of the dialysis cycle.
While it is not possible to determine the exact reason-
ing for neighboring transplantation centers to decline the
organs, discussions with the Organ Procurement Organi-
zation (OPO) highlighted genuine concern regarding the
feasibility of perioperative dialysis. A recent study postulated
that hemodialysis machines employing a photodetector con-
sisting of a single optical emitter designed to detect light
scatter and signal drop off are unlikely to be affected by
hydroxocobalamin whereas those using a dual LED array
that depends on light absorption are susceptible [22, 23].
In congruence with this explanation, a multidisciplinary
discussion was held at our institution prior to transplantation
at which time it was confirmed the dialysis machine leak
alarm could be overridden should dialysis be required.
5. Conclusion
Althoughwe present only two cases, our experience reiterates
that kidneys from donors treated with hydroxocobalamin
can be used with good long-term outcome. Furthermore, we
present the first documented case of successful perioperative
intermittent HD following transplantation of an allograft
exposed to hydroxocobalamin.
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